Wednesday Aug 27
A study of docetaxel and irinotecan in children and young adults with ...
Patients with Ewing sarcoma family of tumors who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options.
Tue Aug 26, 2014
BIND Therapeutics to Present Data at the 26th EORTC-NCI-AACR Symposium
The meeting, which is hosted by the . BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel.
Wed Aug 20, 2014
EGFR biomarkers predict NSCLC response to vandetanib
Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel .
Wed Aug 13, 2014
Breast Cancer Chemotherapy Varies Widely: Study Raises Questions About Early Treatment Choices
Last month, the Journal of Clinical Oncology reported that six chemotherapy regimens commonly given to patients with early-stage breast cancer vary widely in their side effects.
Thu Aug 07, 2014
OncoGenex Pharmaceuticals Inc. Reports Financial Results For Second Quarter 2014
Conference call to be held on Wednesday, April 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Medivation Reports Second Quarter Financial Results and Provides Corporate Update
U.S. net sales of XTANDI capsules for the quarter, as reported by Astellas Pharma Inc., were $143.7 million .
The clippings of a 300-year-old, 150ft yew hedge can save the lives of cancer patients
It's 33ft wide, 150ft long and 40ft tall, but the massive yew hedge at the Bathurst Estate in the Cotswolds is more than just a 300-year-old horticultural wonder, it's a life-saving tree.
Researchers at University of North Carolina Describe Findings in...
The pharmacokinetics of two cylindrical shaped particles with diameter=80nm; height=320nm and d=200nm; h=200nm were compared to Docetaxel in mice bearing human ovarian carcinoma SKOV-3 flank xenografts."
Wed Aug 06, 2014
Study Data from Konkuk University Update Knowledge of Small...
Editor at Biotech Week -- A new study on Small Interference RNAs is now available.
Findings from University of Tennessee Provides New Data about...
Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance."
Mon Aug 04, 2014
Endocyte: A Rare Biotech Opportunity With Significant Upside Potential
Endocyte is significantly undervalued considering its various ongoing clinical cancer trials and 85% of its market cap being in cash with zero debt.